{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "Pharmacologic Substance[C1909]|Antineoplastic Agent[C274]|Angiogenesis Inhibitor[C1742]" in comments (approximate match)
Status:
US Approved Rx
(2021)
Source:
BLA761166
(2021)
Source URL:
First approved in 2021
Source:
BLA761166
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2014)
Source:
BLA125477
(2014)
Source URL:
First approved in 2014
Source:
BLA125477
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2021)
Source:
BLA761202
(2021)
Source URL:
First approved in 2006
Source:
BLA125156
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2022)
Source:
BLA761268
(2022)
Source URL:
First approved in 2004
Source:
BLA125085
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2002)
Source:
BLA103964
(2002)
Source URL:
First approved in 2002
Source:
BLA103964
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00152477: Phase 2 Interventional Completed Carcinoma
(2005)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00072930: Phase 2 Interventional Completed Prostate Cancer
(2003)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00851045: Phase 2 Interventional Completed Colorectal Cancer (CRC)
(2009)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03033524: Phase 2 Interventional Completed Recurrent Glioblastoma
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:varisacumab [INN]
Source URL:
Class:
PROTEIN
